Thank you, Fuad.
want more to today's little a spend developing I concluding topics. Before call, important X time
is I overdue is on started the something up job is believe first our I and on CEO. This something my day cost-cutting that as therefore First program.
going would under the achieve a and several sales justify of original believed had the new last aggressive spending transaction. maximize the adoption been a that strategic the elsewhere drive growth marketing could in revenues it assumption and operated rate to maintain More a for has, IRIDEX spend. accelerated into where was recently, operating program order spend in to products years, that high and
call, what been this the cost has opening company's gradual in My these had said Steps are time ongoing the ability now the objective expenses underway to the review been in line bring strategic operating ongoing expenses. change approach. extended the reduction with requires support to in program. Scott to a a company's is As accelerate
aggressive the begin XXXX, quarter Starting we changes. in making fourth some of
Our departments, reducing free up capital significant renegotiating to initiatives include contracts supplier cost levels. across all and reduction inventory
designed to increased are our gross will accelerate with global to margins partners we through take improve that engagement manufacturing Additionally, contract steps outsourcing.
a the expects As of breakeven IRIDEX achieve these better to EBITDA initiatives, of XXXX. or result quarter in fourth
I been to thing with time, works before some for that maximize in my company That the on on and aggressively reverse. second final revenues. spending sales also note topic. and have elsewhere total to moving One marketing intention the explained idea has to
on back some to pull spend, we we likely are aggressive As revenues. rate the forgo historic of
are our focus are who We deliver best on we comfortable rates those highest the will forward, opportunities this. And for return value the with competitive and going creation. potential advantages of for us,
into created that will an to goes financial this return our final existence changed with of profile. effect. second advantages have the the reimbursement review they business to week comfortable that commented next will that landscape glaucoma topic, are part believe when we into would report I'm the parties with improved are and LCD into right as leads and materially come happy that the more And by third Many talking revised my be competitive attractive change. strategic
involving not CPC for Recall of to version or quarter the clearly The The is we fourth year, excludes glaucoma used have to and MIGS the case which the the offerings at limitations when we new to IRIDEX. Last are products. last proposed surgery the for year, within presented very CPC that into minimally strategic or LCD agreed devices. MACs, very LCD, are the and is procedure pulled the of that definitions on cyclophotocoagulation any included explicitly was importance updated that directed surprised our reimbursement they product nonetheless in believed policy. final cyclophotocoagulation invasive any significant LCD devices, IRIDEX MIGS changes initial clearly our devices,
excluded the I'll from glaucoma our procedures single first-line original physicians longer may Physicians our the LCD, utilize a may in we draw multiple being ultimately glaucoma procedures reimbursement devices in valuable MIGS treatments. MIGS starting the mild for LCD do and included initially As next week moderate treatment is attention offerings. the explain, final treatment. landscape of change to What glaucoma, has no helped restrictions and for process stack the will the new reimbursement no believe, as longer to
we find for multiple will physician and new their We procedures. with last has procedures utilizing adoption MIGS physicians products American thesis of options believe potential Chicago paradigm Because to month Ophthalmology's tested repeated of Academy the affirmation. IRIDEX significant materially the reimbursement increase received restricted, in during parties and conference glaucoma this
MicroPulse steady booth and physicians observed wet also increase and in our perform We they procedures practice. a stream initiating intention of will their TLT the discussion trainings visiting our their lab number of about participating in to
process. are and with part You made third can these have having our the strategic recent to review be of all assured that related observations conversations we parties experiences we of ongoing
on We you. and conclude that, our future shareholders With will results updating look forward Thank to events. we remarks.
